Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.

@article{Cohen2008AxitinibIA,
  title={Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.},
  author={Ezra E. W. Cohen and Lee S. Rosen and Everett E. Vokes and Merrill S. Kies and Arlene A. Forastiere and Francis Paul Worden and Madeleine A. Kane and Eric Sherman and Sinil Kim and Paul W Bycott and Michael A Tortorici and David R. Shalinsky and Katherine F. Liau and Roger B. Cohen},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2008},
  volume={26 29},
  pages={4708-13}
}
PURPOSE Patients with advanced, incurable thyroid cancer not amenable to surgery or radioactive iodine ((131)I) therapy have few satisfactory therapeutic options. This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer. PATIENTS AND METHODS Patients with thyroid cancer of any histology that was resistant or not appropriate… CONTINUE READING
Highly Influential
This paper has highly influenced 19 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
247 Citations
30 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 247 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Initial results from a phase II trial of motesanib diphosphate (AMG 706) in patients with differentiated thyroid cancer

  • SI Sherman, MJ Schlumberger, J Droz
  • J Clin Oncol 25:303s, 2007
  • 2007

Sorafenib targets BRAF and VEGFR in metastatic thyroid cancer

  • V Gupta, W Puttaswamy, W Lassoued
  • J Clin Oncol 25:303s, 2007
  • 2007

Similar Papers

Loading similar papers…